Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SARS and Avian Flu -- Ignore unavailable to you. Want to Upgrade?

To: RealMuLan who wrote (305)	4/22/2003 10:30:49 PM
From: Torben Noerup Nielsen	Read Replies (1) \| Respond to of 4232

"does that mean this SARS vaccine would be just as hard as HIV vaccine to develop?" Let us not start drawing any conclusions based on AIDS. The latter is a retrovirus and that is completely different. To develop a vaccine for SARS, all you really need is a single unique protein that is invariant across strains and expressed by the virus. This wouldn't give you a perfect vaccine, but I suspect it would be good enough if used widely. It wouldn't necessarily give you humoral immunity, but it would likely stop the progression. A vaccine that is only partly effective is often sufficient from a population point of view. If on average, each infected individual passes the virus to less than one other person, the virus will die out. Torben